DBV Technologies S.A. (EPA:DBV)
France
· Delayed Price · Currency is EUR | Market Cap | 1.04B |
| Revenue (ttm) | 4.80M |
| Net Income (ttm) | -125.15M |
| Shares Out | 295.98M |
| EPS (ttm) | -0.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 605,363 |
| Average Volume | 956,065 |
| Open | 3.540 |
| Previous Close | 3.512 |
| Day's Range | 3.500 - 3.612 |
| 52-Week Range | 1.304 - 4.500 |
| Beta | -0.20 |
| RSI | 52.62 |
| Earnings Date | Apr 30, 2026 |
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. ... [Read more]
Financial Performance
In 2025, DBV Technologies's revenue was $5.64 million, an increase of 35.77% compared to the previous year's $4.15 million. Losses were -$146.95 million, 29.0% more than in 2024.
Financial numbers in USD Financial StatementsNews
DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financi...
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026
DBV Technologies S.A.: DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nas...
DBV Technologies S.A.: DBV Technologies Reports Full Year 2025 Financial Results and Business Update
Châtillon, France, March 26, 2026 DBV Technologies Reports Full Year 2025 Financial Results and Business Update Continued advancing the VIASKIN Peanut Patch clinical development programs in peanut-...
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq...
DBV Technologies Reports Full Year 2025 Financial Results and Business Update
Châtillon, France, March 26, 2026 DBV Technologies Reports Full Year 2025 Financial Results and Business Update Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-al...
DBV Technologies S.A.: DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
Châtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV Technologies...
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
Châtillon, France, March 24, 2026 DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Changes went into effect on Monday, March 23, 2026 DBV Technologies (Eu...
DBV Technologies Transcript: The Citizens Life Sciences Conference 2026
Epicutaneous immunotherapy for peanut allergy in young children is advancing, with two BLAs planned for 2026 and strong clinical efficacy and safety data. Launch preparations are underway, supported by a robust cash position and plans to expand the pipeline to cow’s milk protein.
DBV Technologies to Participate in Upcoming March Investor Conferences
Châtillon, France, March 4, 2026 DBV Technologies to Participate in Upcoming March Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage ...
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting Approximately 83% of children treated with the V...
DBV Technologies Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Two BLAs for Viaskin Peanut targeting children with peanut allergy are planned for 2026, supported by strong efficacy and safety data. Commercial launch is expected in 2027, with a focus on allergists and a differentiated, patch-based therapy. The company is well-funded and preparing for future pipeline expansion.
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
Châtillon, France, February 10, 2026 DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in th...
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
Châtillon, France, January 16, 2026 DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing The ...
Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing
DBV Technologies S.A. (NASDAQ: DBVT) on Tuesday released data from the VITESSE Phase 3 study assessing the safety and efficacy of VIASKIN Peanut patch for peanut-allergic children aged 4 to 7 years.
DBV Technologies Transcript: Study Update
The phase III VITESSE trial in children aged 4–7 met its primary endpoint, showing a 46.6% responder rate and a strong safety profile, paving the way for BLA submission in 2026. The results are consistent across ages one to seven, with high compliance and significant commercial potential.
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
Châtillon, France, November 11, 2025 DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN ® Peanut Patch in Peanut Allergic Children Aged 4-7 Years Comp...
DBV Technologies Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
A novel patch-based immunotherapy for peanut allergy in children is advancing, with two independent programs targeting ages one to seven. The pivotal VITESSE trial is highly powered, with data expected soon, and strong FDA engagement supports regulatory progress. Commercial and manufacturing plans are in place for launch, with robust financials through 2026.
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2 nd Annual Healthcare Innovation Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock M...
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
Chatillion, France, November 3, 2025 DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT)...
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the...
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
Châtillon, France, October 30, 2025 DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – ...